Friday, 24 July 2026 — BB Biotech Interim Report Q2 2026 Available here

BB Biotech Q2 2026 — Video Update Take a look

Friday, 24 July 2026 — BB Biotech Interim Report Q2 2026 Available here

BB Biotech Q2 2026 — Video Update Take a look

Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its interim report and revises its dividend policy

24.07.2026

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2026, which covers the results of its business activities for the first six months of 2026.

Based on the consolidated accounts of BB Biotech AG, a net gain for the period ended June 30, 2026, amounted to CHF 430 mn (loss of CHF 341 mn in H1 2025). In the second quarter, a gain of CHF 451 mn (loss of CHF 100 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG has revised its dividend policy with effect from financial year 2026. The company will in future target an annual dividend yield of 3-5%, replacing the previous fixed policy.

The interim report as at June 30, 2026, is available under www.bbbiotech.ch.

 

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zürich, Schweiz, Tel. +41 44 267 67 00 

Head BB Biotech Team
Dr. Christian Koch 

Head Investor Relations
ir@bbbiotech.com
Rachael Burri, rbu@bellevue.ch

Media Relations
Fabienne Tresch, ftr@bellevue.ch